Boehringer and Walgreens Partner to Improve Diversity in Clinical Trials
In this partnership, Boehringer Ingelheim will utilise specific US-based pharmacy store chain Walgreens sites for clinical trials focusing on individuals
Read more
Clinical Trials
Ventus’ NLRP3 Inhibitor Shows Potential for CNS Diseases in Phase 1 Trial
Ventus Therapeutics, a US-based clinical-stage biopharmaceutical company leveraging its exclusive structural biology and computational chemistry platform, ReSOLVE™, has disclosed promising
Read more
Pfizer’s ABRYSVO® Shows Promising Results in Phase 3 Trial Targeting RSV Prevention in High-Risk Adults
Pfizer has announced encouraging findings from its ongoing pivotal Phase 3 clinical trial, known as MONeT (RSV IMmunizatiON Study for
Read more
Machine Learning Tissue Classifiers Power AI in Clinical Research
Machine learning tissue classifiers are one of the most powerful and promising AI-based clinical research solutions for all types of
Read more
Vaxart Awarded $9.27 Mill Funding for Phase 2b Trial of Oral Pill COVID-19 Vaccine
American clinical-stage biotechnology company Vaxart, Inc. has announced that the United States Biomedical Advanced Research and Development Authority (BARDA) granted
Read more
Phase 3 Trial Data Shows Novartis Lutathera® Effective as First-line Treatment for GEP-NETs
Lutathera®, developed by Swiss drugmaker Novartis has demonstrated a substantial 72% reduction in the risk of disease progression or death
Read more
AbbVie Launches PRODUODOPA® in the EU for Advanced Parkinson’s Disease
AbbVie has introduced PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union to address advanced Parkinson’s disease. AbbVie (NYSE: ABBV) recently announced the
Read more
Moderna Announces Encouraging Phase 1/2 Results for Combo Influenza and COVID-19 Vaccine
Moderna, Inc. has announced positive interim findings from its Phase 1/2 trial of mRNA-1083, an innovative dual-purpose vaccine targeting both
Read more
AstraZeneca’s Fasenra Achieves Primary Objective in Phase III Trial in EGPA
The MANDARA Phase III trial marks the first head-to-head comparison of biologics in treating eosinophilic granulomatosis with polyangiitis (EGPA), putting
Read more
Coya Therapeutics’ COYA 301 (interleukin-2) Shows Promising Results in Open Label Alzheimer’s Study
Coya Therapeutics’ investigational low-dose interleukin-2 (IL-2) for subcutaneous administration, COYA 301, has been found to increase Treg function and halt
Read more